Improving natural killer cell cancer immunotherapy - Test2 - elhamkhani - TriplyDB

Improving natural killer cell cancer immunotherapy

Improving natural killer cell cancer immunotherapy

http://www.wikidata.org/entity/Q28087719

about

Natural Killer Cell Diversity in Viral Infection: Why and How Much?Harnessing NK Cell Memory for Cancer Immunotherapy.Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity.Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner.Cd226-/- natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo.Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.First-in-human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse after Transplantation.Evidence-Based Review of BioBran/MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment.

P2860

Q37252674-6EECB57A-E593-471B-B1EF-6389AC611305 Q38988913-CABB1D16-118C-4896-8CD0-40749350BC5A Q41497471-273CA4A3-75B0-4568-9BC9-30ED77C882CA Q41619501-51051449-D15F-4C13-BF60-28F74B3BDA66 Q41991684-B56807EE-5FE3-42D5-B7EC-905BC5160A8E Q42660142-943D4738-93BC-4482-9615-B4D8C59A39ED Q47129350-092E509A-BEB1-445A-9864-54DE39F7C227 Q47970705-BE1F5C8E-9A00-461F-BD8C-07742F1157C6 Q48375822-DA723C8C-1EB8-4BEB-9410-509424F7AF70 Q49791810-6081342C-6C0C-436F-AFC2-18917FD0A0D9 Q50075581-89A15606-96D3-40FE-A607-8766B84EFF39

P2860

Improving natural killer cell cancer immunotherapy

http://www.wikidata.org/entity/Q28087719

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Improving natural killer cell cancer immunotherapy

@ast

Improving natural killer cell cancer immunotherapy

@en

Improving natural killer cell cancer immunotherapy

@nl

type

label

Improving natural killer cell cancer immunotherapy

@ast

Improving natural killer cell cancer immunotherapy

@en

Improving natural killer cell cancer immunotherapy

@nl

prefLabel

Improving natural killer cell cancer immunotherapy

@ast

Improving natural killer cell cancer immunotherapy

@en

Improving natural killer cell cancer immunotherapy

@nl

P1433

Q28087719-B51A43E5-FA25-4378-9814-9CAA03C68730

P1476

Q28087719-78083520-3316-4DD8-A1BE-F687D9CA7F08

P2093

Q28087719-0362CB31-1279-485E-8095-020848228BCA

Q28087719-5E4F1CF7-C844-4FC9-8DC7-784F2F0EFB10

P2860

Q28087719-01552F33-79B5-4BBE-82F0-B988E7B58849

Q28087719-0386D4CF-DF44-443A-ADBF-EF2D941B0C0D

Q28087719-08401ABF-DBEB-4425-AB52-DC42D7D5CAF1

Q28087719-0B47D654-45D8-4DAC-8CA2-6203F0FEC4F4

Q28087719-0D54085D-8C17-4081-A0B7-586830492C36

Q28087719-104DFA9A-383D-4627-BBD6-F56E89FA0959

Q28087719-10C82CFD-D597-4CAC-8A85-592F0B9DD39C

Q28087719-1955275F-C067-47BC-A1F5-723C4D4CE7E9

Q28087719-1CA8B5BB-F39E-492A-8FDF-BEF6173656E0

Q28087719-1CD68741-81C3-4E91-AFFB-CA7FBD94F02F

P304

Q28087719-52041819-74E9-4ABB-B593-5FBBB25D41AD

P31

Q28087719-6E64FEBA-D2CA-4384-A416-CE5A0F2FE755

P3181

Q28087719-72FD939F-0715-4FD0-85C2-38C0B4853A85

P356

Q28087719-110A1D2B-E1CD-4561-A374-A6131733B422

P407

Q28087719-F008307F-EA39-4173-920D-BF2D3B2B1A4C

P433

Q28087719-A431554F-8595-4434-A1A6-9F359613C88F

P478

Q28087719-E495BD78-5796-4953-992D-6A46C457A74C

P50

Q28087719-C791C7D8-3D6B-4D83-8E36-A07CD33E1BFF

P577

Q28087719-0A474101-92A4-4782-A7CC-D635863A466A

P698

Q28087719-F6F5D84E-12B3-473A-B147-5B00DDC93085

P921

Q28087719-729C2C5E-EA4A-413F-883C-BBDB934EB97F

P932

Q28087719-474ED1A0-0814-40E2-AD74-1BE2383880CC

P3181

P356

MOT.0000000000000243

P1433

Current opinion in organ transplantation

P1476

Improving natural killer cell cancer immunotherapy

@en

P2093

Rizwan Romee

http://www.w3.org/2001/XMLSchema#string

Todd A Fehniger

http://www.w3.org/2001/XMLSchema#string

P2860

Advantages and applications of CAR-expressing natural killer cells

Myeloid-derived suppressor cells as regulators of the immune system

Functions of natural killer cells

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

The immune contexture in human tumours: impact on clinical outcome

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

P304

671-680

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2899806

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/MOT.0000000000000243

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Melissa M Berrien-Elliott

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26414502

http://www.w3.org/2001/XMLSchema#string

P921

P932

4635041

http://www.w3.org/2001/XMLSchema#string